Indication
as monotherapy for the treatment of locally advanced, unresectable non-small cell lung cancer (NSCLC) in adults whose tumours express programmed cell death ligand 1 (PD-L1) on ≥1% of tumour cells (TCs) and whose disease has not progressed following platinum-based chemoradiation therapy (CRT)

Medicine details

Medicine name:
durvalumab (Imfinzi)
SMC ID:
SMC2156
Pharmaceutical company
AstraZeneca UK Ltd
BNF chapter
Submission type
Full submission
Status
Advice due date:
Q3 2019
SMC meeting date:
Q2 2019
Patient group submission deadline:
04 March 2019